Advanced search
1 file | 1.43 MB Add to list

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) : an update (2014-2018)

(2020) CLINICAL NEUROPHYSIOLOGY. 131(2). p.474-528
Author
Organization
Project
Abstract
A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a Hl-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance. (C) 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.
Keywords
Physiology (medical), Sensory Systems, Neurology, Clinical Neurology, Cortex, Indication, Neurology, Neuromodulation, Noninvasive brain stimulation, Psychiatry, Treatment, THETA-BURST STIMULATION, DORSOLATERAL PREFRONTAL CORTEX, OBSESSIVE-COMPULSIVE DISORDER, NONINVASIVE BRAIN-STIMULATION, SHAM-CONTROLLED-TRIAL, HIGH-FREQUENCY RTMS, MAJOR DEPRESSIVE DISORDER, TREATMENT-RESISTANT DEPRESSION, PREDOMINANT NEGATIVE SYMPTOMS, AUDITORY VERBAL HALLUCINATIONS

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.43 MB

Citation

Please use this url to cite or link to this publication:

MLA
Lefaucheur, Jean-Pascal, et al. “Evidence-Based Guidelines on the Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (RTMS) : An Update (2014-2018).” CLINICAL NEUROPHYSIOLOGY, vol. 131, no. 2, 2020, pp. 474–528, doi:10.1016/j.clinph.2019.11.002.
APA
Lefaucheur, J.-P., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., … Ziemann, U. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) : an update (2014-2018). CLINICAL NEUROPHYSIOLOGY, 131(2), 474–528. https://doi.org/10.1016/j.clinph.2019.11.002
Chicago author-date
Lefaucheur, Jean-Pascal, André Aleman, Chris Baeken, David H. Benninger, Jérôme Brunelin, Vincenzo Di Lazzaro, Saša R. Filipović, et al. 2020. “Evidence-Based Guidelines on the Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (RTMS) : An Update (2014-2018).” CLINICAL NEUROPHYSIOLOGY 131 (2): 474–528. https://doi.org/10.1016/j.clinph.2019.11.002.
Chicago author-date (all authors)
Lefaucheur, Jean-Pascal, André Aleman, Chris Baeken, David H. Benninger, Jérôme Brunelin, Vincenzo Di Lazzaro, Saša R. Filipović, Christian Grefkes, Alkomiet Hasan, Friedhelm C. Hummel, Satu K. Jääskeläinen, Berthold Langguth, Letizia Leocani, Alain Londero, Raffaele Nardone, Jean-Paul Nguyen, Thomas Nyffeler, Albino J. Oliveira-Maia, Antonio Oliviero, Frank Padberg, Ulrich Palm, Walter Paulus, Emmanuel Poulet, Angelo Quartarone, Fady Rachid, Irena Rektorová, Simone Rossi, Hanna Sahlsten, Martin Schecklmann, David Szekely, and Ulf Ziemann. 2020. “Evidence-Based Guidelines on the Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (RTMS) : An Update (2014-2018).” CLINICAL NEUROPHYSIOLOGY 131 (2): 474–528. doi:10.1016/j.clinph.2019.11.002.
Vancouver
1.
Lefaucheur J-P, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) : an update (2014-2018). CLINICAL NEUROPHYSIOLOGY. 2020;131(2):474–528.
IEEE
[1]
J.-P. Lefaucheur et al., “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) : an update (2014-2018),” CLINICAL NEUROPHYSIOLOGY, vol. 131, no. 2, pp. 474–528, 2020.
@article{8650534,
  abstract     = {{A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206]. These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a Hl-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respectively, in Parkinson's disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spasticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recommendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance. (C) 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.}},
  author       = {{Lefaucheur, Jean-Pascal and Aleman, André and Baeken, Chris and Benninger, David H. and Brunelin, Jérôme and Di Lazzaro, Vincenzo and Filipović, Saša R. and Grefkes, Christian and Hasan, Alkomiet and Hummel, Friedhelm C. and Jääskeläinen, Satu K. and Langguth, Berthold and Leocani, Letizia and Londero, Alain and Nardone, Raffaele and Nguyen, Jean-Paul and Nyffeler, Thomas and Oliveira-Maia, Albino J. and Oliviero, Antonio and Padberg, Frank and Palm, Ulrich and Paulus, Walter and Poulet, Emmanuel and Quartarone, Angelo and Rachid, Fady and Rektorová, Irena and Rossi, Simone and Sahlsten, Hanna and Schecklmann, Martin and Szekely, David and Ziemann, Ulf}},
  issn         = {{1388-2457}},
  journal      = {{CLINICAL NEUROPHYSIOLOGY}},
  keywords     = {{Physiology (medical),Sensory Systems,Neurology,Clinical Neurology,Cortex,Indication,Neurology,Neuromodulation,Noninvasive brain stimulation,Psychiatry,Treatment,THETA-BURST STIMULATION,DORSOLATERAL PREFRONTAL CORTEX,OBSESSIVE-COMPULSIVE DISORDER,NONINVASIVE BRAIN-STIMULATION,SHAM-CONTROLLED-TRIAL,HIGH-FREQUENCY RTMS,MAJOR DEPRESSIVE DISORDER,TREATMENT-RESISTANT DEPRESSION,PREDOMINANT NEGATIVE SYMPTOMS,AUDITORY VERBAL HALLUCINATIONS}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{474--528}},
  title        = {{Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) : an update (2014-2018)}},
  url          = {{http://dx.doi.org/10.1016/j.clinph.2019.11.002}},
  volume       = {{131}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: